De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression

p16 is a tumor suppressor encoded by the CDKN2A gene whose expression is lost in ~50% of all human cancers. In its canonical role, p16 inhibits the G1-S phase cell cycle progression through suppression of cyclin dependent kinases. Interestingly, p16 also has roles in metabolic reprogramming, and we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tangudu, Naveen Kumar, Buj, Raquel, Wang, Hui, Wang, Jiefei, Cole, Aidan R., Uboveja, Apoorva, Fang, Richard, Amalric, Amandine, Sajjakulnukit, Peter, Lyons, Maureen A., Cooper, Kristine, Hempel, Nadine, Snyder, Nathaniel W., Lyssiotis, Costas A., Chandran, Uma R., Aird, Katherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369956/
https://www.ncbi.nlm.nih.gov/pubmed/37503050
http://dx.doi.org/10.1101/2023.07.15.549149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369956/
https://www.ncbi.nlm.nih.gov/pubmed/37503050
http://dx.doi.org/10.1101/2023.07.15.549149

Ejemplares similares